medical

OUE Lippo Healthcare JV to manage 3 hospitals in major Chinese cities

SINGAPORE (Dec 31): OUE Lippo Healthcare will manage three medical facilities in Shanghai, Chongqing and Nanjing through to a joint-venture agreement.

Named China Merchants Lippo Hospital Management (Shenzhen), the company is a 50:50 JV between OUE Lippo’s indirect wholly-owned subsidiary Lippo Healthcare and China Merchants Landmark (Shenzhen), a member of China Merchants Group (CMG).

Indonesia billionaire family reshuffles empire on currency rout

SINGAPORE/JAKARTA (Sept 19): Southeast Asia’s billionaire Riady family is reshuffling its health-care holdings as its core property business grapples with the emerging-market rout.

Time needed to heal TalkMed's wound from CEO Ang's suspension: RHB

SINGAPORE (Apr 27): RHB is maintaining its “neutral” call on TalkMed Group with a lower target price of 70 cents from 72 cents previously after the group reported a weak 1Q18 set of financial results.  

To recap, the private healthcare services group saw its topline fall 25.7% on-year due to the eight-month suspension of its key revenue contributor and CEO, Ang Peng Tiam, who only resumed his medical duties last month on Mar 25.

Tianjin Zhongxin Pharma on its way to a stellar 2018 & beyond, says UOB

SINGAPORE (Apr 2): UOB Kay Hian is keeping Tianjin Zhongxin Pharmaceutical Group at “buy” with a higher target price of US$1.66 ($2.17), pegged to peer average of 14.1 times FY18 earnings.

This comes after Tianjin Zhongxin Pharma exceeded expectations in 4Q17 due to a net profit surge, bringing full-year PATMI to RMB473.3 million, 4.5% above UOB’s full-year forecast on higher 4Q blended gross margin after factoring in a price hike for the group’s key product, “Su Xiao Jiu Xin” pills.

More acquisitions likely for Singapore Medical Group in 2018

SINGAPORE (Mar 1): UOB Kay Hian is maintaining its “buy” call on Singapore Medical Group (SMG) with a P/E-based target price of 83 cents, pegged to the peer average FY18 P/E ratio of 26.8 times.

In a Thursday report, analyst Nicholas Leow highlights that the group’s 4Q17 results announced yesterday were in line with UOB’s estimates with FY17 earnings more than trebling to $8.5 mil due to earnings-accretive acquisitions made during the year – which in turn added other disciplines to the SMG specialist verticals.

Aoxin takes a big bite of China's buoyant dental market

SINGAPORE (Jan 31): Oral medicine specialist Dr Shao Yongxin has always been fascinated by the artistry and technical expertise involved in the practice of dentistry.

The standards of excellence demanded by the profession, and Shao's willingness to strive for perfection in his craft, were catalysts for his three decade-long journey in stomatology, a science that deals with the mouth and its diseases.

"I felt that dentistry, in particular, prosthodontics, offered a limitless space for me to constantly improve myself and hone my skills," Shao said.

Ang Peng Tiam's suspension to remain key near-term overhang on TalkMed: CIMB

SINGAPORE (Jan 8): CIMB is maintaining its “hold” call on TalkMed Group with a lower target price of 68 cents from 92 cents previously, after cutting FY17-19F earnings per share (EPS) estimates by 18-21% to factor anticipated earnings losses from the recent suspension of the group’s key doctor and CEO, Ang Peng Tiam, on the grounds of professional misconduct in 2010.

Ping An is now second largest shareholder of Fullerton Healthcare after $163.3 mil investment

SINGAPORE (Nov 28): Fullerton Healthcare Corporation, which deferred plans for an IPO last year, has received a significant investment of more than RMB800 million ($163.3 million) from Ping An Capital.

Ping An Capital is a core equity investment platform of Ping An Insurance Company of China.

Robust growth momentum keeps Health Management at 'buy'

SINGAPORE (Nov 16): Maybank Kim Eng is maintaining its “buy” call on Health Management International (HMI) with a target price of 80 cents, after the group’s 1Q18 core earnings came in line with expectations to make up 27% of the research house’s FY18E projections.

See: Health Management 1Q earnings more than double

Trendlines Medical makes maiden investment in medical device startup

SINGAPORE (Oct 16): Trendlines Medical Singapore, a 76.43%-owned subsidiary of Catalist-listed Israeli company The Trendlines Group, has made its first investment by committing a total of US$60,000 ($81,150) to a medical device start-up, InterVaal.

InterVaal is developing a urological catheter to address catheter associated urinary tract infection.

Trendlines says that its in-house innovation unit, Trendlines Labs, will work with InterVaal’s Singapore-based staff to develop the catheter and conduct clinical trials in Singapore.

Be informed of the stories that matter

Subscribe

Be informed of the stories that matter